Frontlight ResearchEarly access
TerminatedPhase 2
Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
Key facts
- Who runs it
- Neurocrine Biosciences
- Where
- Aurora, Cleveland, Durham, Miami, Orange, Rochester, and Washington D.C., United StatesSee the 7 sitesAlso in 4 other countries, 5 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 19 people enrolled
- Started
- 7 Jun 2022
- Ended
- 27 Jan 2025
- Type of study
- Interventional
- Treatments tested
- NBI-827104
- Record updated
- 13 February 2026
- Why it stopped
- Business decision
Who can take part
- Age
- 4 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- For participants who enroll directly following the completion of the Study NBI-827104-CSWS2010:
- Completed 12 weeks of treatment in Study NBI-827104-CSWS2010; For Participants Who Do Not Enroll Directly from or Did Not Participate in Study NBI-827104-CSWS2010:
- Have diagnosis of EECSWS confirmed by the Diagnosis Confirmation Panel (DCP)
Who cannot take part
- Presence of relevant neurological disorders other than EECSWS and its underlying conditions as judged by the investigator. Symptomatic conditions underlying EECSWS (for example, neonatal strokes) have to be stable for at least 1 year prior to screening
- Planned surgical intervention related to structural abnormalities of the brain from screening through the Week 6 Visit
- Used any active investigational drug other than NBI-827104 in the context of a clinical study within 30 days or 5 half-lives (whichever is longer) before screening or plans to use such an investigational drug (other than NBI-827104) during the study
- Have developed any other disorder for which the treatment takes priority over treatment of EECSWS or is likely to interfere with study treatment or impair treatment compliance; For Participants Who Do Not Enroll Directly from or Did Not Participate in Study NBI-827104-CSWS2010:
- Have developed any other disorder for which the treatment takes priority over treatment of EECSWS or is likely to interfere with study treatment or impair treatment compliance
- Clinically relevant findings related to cardiovascular or laboratory parameters at screening as determined by the investigator
- For participants who enroll directly following the completion of the Study NBI-827104-CSWS2010:
- Body weight <15 kg at Day 1
Where in United States
Also in 4 other countries, 5 sites
- Aurora, ColoradoHospital not named in the registry
- Cleveland, OhioHospital not named in the registry
- Durham, North CarolinaHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Orange, CaliforniaHospital not named in the registry
- Rochester, New YorkHospital not named in the registry
- Washington D.C., District of ColumbiaHospital not named in the registry
About the trial
What the trial wants to find out
The primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).
The group in the trial
- NBI-827104Treatment being tested
NBI-827104 administered orally
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
- Record updated
- 13 February 2026